Title
PHASE II STUDY OF IBERDOMIDE (CC220) MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMAOverview / Summary
Study details
The study is sponsored by EMN Foundation and will focus on maintenance during first line of therapy.
Enrolment is planned for January 2021. Participating countries will include:
Italy (5 sites)
Greece (2 sites)
France (4 sites)
Netherland (5 sites)
Patient eligibility criteria
Newly diagnosed multiple myeloma (NDMM) patients in at least partial response (PR) after induction with proteasome inhibitors (PIs) plus IMIDs and single or double ASCT
Publications
No publications connected to this trial at the moment